CRC Research Update — October 06, 2026
Today's colorectal cancer research highlights
liver-mets
A collection of 85 issues
CRC Research Update — October 05, 2026
Today's colorectal cancer research highlights
SPP1+ macrophages linked to chemotherapy resistance in colorectal liver metastasis
Skip to content
The CRC Digest
◇ RESEARCH
SPP1+ macrophages linked to chemotherapy resistance in colorectal liver metastasis
Single-cell RNA sequencing identified a macrophage subpopulation marked by elevated SPP1 expression that is significantly enriched in patients who respond insufficiently to neoadjuvant chemotherapy; these cells suppress CD8+ T cell function through the
CRC Research Update — October 03, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 27, 2026
Today's colorectal cancer research highlights
TIGIT+ CD4+ T Cells in Liver Metastases Linked to Shorter Survival
Skip to content
The CRC Digest
◇ RESEARCH
TIGIT+ CD4+ T Cells in Liver Metastases Linked to Shorter Survival
Flow cytometric profiling of 17 patients undergoing liver metastasectomy found that enrichment of TIGIT+ CD4+ T cells in colorectal cancer liver metastases was associated with shorter overall survival, highlighting differences in the
CRC Research Update — September 24, 2026
Today's colorectal cancer research highlights
Aspirin after liver metastasis treatment tested in phase 3 trial
Skip to content
The CRC Digest
◆ TRIAL DATA
Aspirin after liver metastasis treatment tested in phase 3 trial
The ASAC trial randomly assigned patients who had undergone curative-intent treatment for colorectal cancer liver metastases to aspirin or placebo to assess whether adjuvant aspirin improves disease-free survival. (Lancet Gastroenterol Hepatol)
This
CRC Research Update — September 23, 2026
Today's colorectal cancer research highlights
Review Examines Immunotherapy in Liver Metastases Beyond MMR Status
Skip to content
The CRC Digest
◇ RESEARCH
Review Examines Immunotherapy in Liver Metastases Beyond MMR Status
A review explored immunotherapy approaches in colorectal cancer liver metastases, examining the hepatic metastatic niche beyond traditional mismatch repair considerations. (Frontiers in Immunology)
This content is informational only and does not constitute medical advice.